Form 8-K

8-K — ACCENDRA HEALTH INC/VA/

Accession: 0001104659-26-097517

Filed: 2026-08-17

Period: 2026-08-17

CIK: 0000075252

SIC: 5047 (WHOLESALE-MEDICAL, DENTAL & HOSPITAL EQUIPMENT & SUPPLIES)

Item: Regulation FD Disclosure

Item: Financial Statements and Exhibits

Documents

8-K — tm2622667d5_8k.htm (Primary)

EX-99.1 — EXHIBIT 99.1 (tm2622667d5_ex99-1.htm)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — FORM 8-K

8-K (Primary)

Filename: tm2622667d5_8k.htm · Sequence: 1

false

0000075252

2026-08-17

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):

August 17, 2026

Accendra

Health, Inc.

(Exact name of registrant as specified in its charter)

Virginia

001-09810

54-1701843

(State

or other jurisdiction of

incorporation or organization)

(Commission

File Number)

(I.R.S.

Employer Identification No.)

4435

Waterfront Drive, Suite 300,

Glen Allen, Virginia

23060

(Address

of principal executive offices)

(Zip

Code)

(804) 277-4304

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of

the Act:

Title of each class

Trading

Symbol(s)

Name of each exchange

on which registered

Common Stock, $2 par value per share

ACH

New York Stock Exchange

Check the appropriate box below if the Form 8-K filing is intended

to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.

below):

¨ Written

communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting

material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement

communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement

communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth

company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities

Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging

growth company ¨

an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying

with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 7.01 Regulation FD Disclosure.

On August 17, 2026, the Company

issued a press release providing updates on its capital allocation plans, including the Company’s decision not to implement an at-the-market

equity issuance program, the opportunistic sale of two non-core assets and the status of the Company’s Chief Executive Officer succession

process.

The Company is furnishing

the press release attached hereto as Exhibit 99.1 pursuant to Item 7.01 of Form 8-K. In accordance with General Instruction

B.2 of Form 8-K, the information in this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for the

purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section,

nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”),

except as shall be expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.

Description

99.1

Press Release dated August 17, 2026

104

Cover Page Interactive Data File (the cover page XBRL

tags are embedded in the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities

Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ACCENDRA HEALTH, INC.

August 17, 2026

/s/ Jonathan A. Leon

Jonathan A. Leon

Executive Vice President and Chief Financial Officer

EX-99.1 — EXHIBIT 99.1

EX-99.1

Filename: tm2622667d5_ex99-1.htm · Sequence: 2

Exhibit 99.1

Accendra Health

Updates on Capital Allocation and CEO Succession Timing Plans

RICHMOND,

VA – August 17, 2026 – Accendra Health (the “Company”) is providing an update on its capital allocation

plans and the timeline for the replacement of its chief executive officer.

Given recent market conditions, the Company has

determined that it is in the best interest of stakeholders not to put in place an at-the-market issuance program. The program was intended

to allow the Company to opportunistically issue modest amounts of equity over time, with the proceeds to be used to reduce outstanding

indebtedness, including debt trading at discounts to par value. The program was never intended as a source of liquidity for the Company.

Not implementing the program will have no impact on the Company’s results of operations or published guidance.

In addition, with increasing cash collections

and strengthening progress in resolving payor collection issues, the Company remains confident in its liquidity position. The Company

was undrawn on its $300 million revolving credit facility at the end of the second quarter and does not expect to rely on that facility

other than to address occasional working capital fluctuations. The Company remains committed to strengthening its balance sheet and reducing

leverage.

The Company is also providing an update on the

opportunistic sale of two non-core assets. The first of these sales closed in the third quarter and the second is expected to close before

the end of the year. Together these sales represent a cash injection of approximately $45 million in the third and fourth quarters of

the year and will have de minimus impact on the Company’s Adjusted EBITDA.

The Company is also providing an update on its

announcement regarding the CEO succession plan. The Company’s Board of Directors has maintained a comprehensive, long-standing CEO

succession planning process supported by leading executive search and advisory firms. Following Mr. Pesicka’s formal announcement

of his intention to retire by the end of 2026, the Board promptly advanced the next phase of its succession process and has been actively

evaluating candidates. The Board has identified a strong pipeline of potential candidates with the experience and capabilities needed

to lead the Company into its next phase of growth. The Board currently expects to announce a successor by mid-September 2026, positioning

the Company for a timely leadership transition well ahead of Mr. Pesicka’s planned retirement. Mr. Pesicka will continue to serve

as CEO until his successor is in place and will serve in an advisory capacity following the transition to support continuity and an orderly

handoff.

Safe Harbor

This

release is intended to be disclosure through methods reasonably designed to provide broad, non-exclusionary distribution to the public

in compliance with the SEC’s Fair Disclosure Regulation. This release contains certain “forward looking” statements

made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements include, but are

not limited to, the statements in this release regarding our future prospects and performance, including our expectations with respect

to our financial performance, our 2026 financial results, our expectations regarding the performance of our business following the completion

of the sale of the Products & Healthcare Services business, uncertainty about the time required to select and appoint the Company’s

next President and CEO, our cost saving initiatives, future indebtedness and growth, industry trends, as well as statements related to

our expectations regarding the performance of our business, including our ability to address macro and market conditions. Forward-looking

statements involve known and unknown risks and uncertainties that may cause our actual results in future periods to differ materially

from those projected or contemplated in the forward-looking statements. Investors should refer to the Company’s Annual Report on

Form 10-K for the year ended December 31, 2025, filed with the SEC on February 20, 2026, including the section captioned “Item 1A.

Risk Factors,” as applicable, and subsequent quarterly reports on Form 10-Q and current reports on Form 8-K filed with or furnished

to the SEC, for a discussion of certain known risk factors that could cause the Company’s actual results to differ materially from

its current estimates. These filings are available at www.accendrahealth.com. Given these risks and uncertainties, the Company

can give no assurance that any forward-looking statements will, in fact, transpire and, therefore, cautions investors not to place undue

reliance on them. The Company specifically disclaims any obligation to update or revise any forward-looking statements, whether as a result

of new information, future developments or otherwise.

About Accendra Health

Accendra

Health, Inc. (NYSE: ACH) is a leading nationwide provider of products, technology, and services that support health beyond the hospital

for millions of people each year. We connect patients, providers, and insurers, delivering innovative solutions that help promote better

health outcomes and improve quality of life for people living with chronic, complex health conditions. Backed by the industry-leading

expertise of our Apria and Byram brands, Accendra Health is reimagining the future of home-based care. To learn more about our broad portfolio

of essentials for diabetes, sleep health, wound care, respiratory care, urology, and ostomy, visit www.accendrahealth.com.

CONTACT:

Investors

Will Parrish

Vice President | Strategy, Corporate Development, & Investor

Relations

Investor.Relations@accendra.com

Media

Darla Turner

media@accendra.com

ACH-CORP

ACH-IR

SOURCE:

Accendra Health, Inc.

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 7

v3.26.1

Cover

Aug. 17, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Aug. 17, 2026

Entity File Number

001-09810

Entity Registrant Name

Accendra

Health, Inc.

Entity Central Index Key

0000075252

Entity Tax Identification Number

54-1701843

Entity Incorporation, State or Country Code

Entity Address, Address Line One

4435

Waterfront Drive, Suite 300

Entity Address, City or Town

Glen Allen

Entity Address, State or Province

Entity Address, Postal Zip Code

23060

City Area Code

804

Local Phone Number

277-4304

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common Stock, $2 par value per share

Trading Symbol

ACH

Security Exchange Name

NYSE

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration